Amicus Therapeutics (FOLD) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to -$263.9 million.
- Amicus Therapeutics' Enterprise Value fell 565.87% to -$263.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$263.9 million, marking a year-over-year decrease of 565.87%. This contributed to the annual value of -$249.9 million for FY2024, which is 1266.74% up from last year.
- Per Amicus Therapeutics' latest filing, its Enterprise Value stood at -$263.9 million for Q3 2025, which was down 565.87% from -$231.0 million recorded in Q2 2025.
- In the past 5 years, Amicus Therapeutics' Enterprise Value registered a high of -$231.0 million during Q2 2025, and its lowest value of -$557.0 million during Q3 2021.
- Over the past 5 years, Amicus Therapeutics' median Enterprise Value value was -$280.3 million (recorded in 2023), while the average stood at -$322.7 million.
- As far as peak fluctuations go, Amicus Therapeutics' Enterprise Value plummeted by 2373.4% in 2021, and later soared by 3915.08% in 2022.
- Amicus Therapeutics' Enterprise Value (Quarter) stood at -$482.5 million in 2021, then surged by 39.15% to -$293.6 million in 2022, then grew by 2.52% to -$286.2 million in 2023, then rose by 12.67% to -$249.9 million in 2024, then fell by 5.58% to -$263.9 million in 2025.
- Its last three reported values are -$263.9 million in Q3 2025, -$231.0 million for Q2 2025, and -$250.6 million during Q1 2025.